Daratumumab for Treatment of Acute Antibody-Mediated Rejection in a Pediatric Kidney Transplant Recipient
{{output}}
Background: Daratumumab, an anti-CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody-mediated rejection (ABMR) following kidney transplantation in adults. ... ...
